Co-Diagnostics Flags Going Concern as Cash Drops to $3.6M

summarizeSummary

Co-Diagnostics' Q2 10-Q shows a going concern warning, cash down to $3.6M, and a $15.4M six-month net loss. A subsequent warrant inducement raised $2.67M but adds dilution risk.

check_boxKey Events · Earnings and Guidance · CODX

• Going Concern Warning

  Management concluded substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.

• Cash Burn Accelerates

  Cash and cash equivalents fell to $3.6 million as of June 30, 2026, from $11.9 million at December 31, 2025. Net cash used in operating activities was $15.0 million for the six months.

• Net Loss Widens

  Net loss for the six months ended June 30, 2026 was $15.4 million, compared to $15.3 million in the prior year period. Revenue was only $312,084.

• Subsequent Warrant Inducement

  On July 30, 2026, the Company entered into an inducement agreement to exercise existing warrants for $2.67 million in gross proceeds, issuing 3,404,724 new warrants at $1.56 per share, not exercisable until stockholder approval.

auto_awesomeAnalysis · CODX · Industrial Applications And Services

Co-Diagnostics' Q2 2026 10-Q reveals a going concern warning, with cash down to $3.6 million from $11.9 million at year-end. The company burned $15 million in operating cash in six months and posted a $15.4 million net loss. Management states substantial doubt exists about its ability to continue as a going concern within 12 months. The filing also discloses a subsequent warrant inducement deal raising $2.67 million, but the new warrants require stockholder approval and add significant potential dilution. This is a critical survival signal for a micro-cap company with minimal revenue.